TheraRadar
Clinical-Stage Companies / Addpharma

Addpharma

Pre-Approval PRO BETA
50
Total Trials
12
Phase 3
3
Phase 2
8
Recruiting
379
Score

Pipeline by Phase

Phase 3
12
Phase 2
3
Phase 1
35

Therapeutic Focus

Hypertension Mixed Dyslipidemia Hypertension,Essential Hyperlipidemias Primary Hypercholesterolemia

Clinical Trials (50)

NCT05400317 Phase 3 RECRUITING

A Study to Evaluate the Efficacy and Safety of AD-218

Started: 7/27/2022

NCT06291207 Phase 3 RECRUITING

A Study to Evaluate the Efficacy and Safety of AD-224

Started: 4/15/2024

NCT06441630 Phase 3 RECRUITING

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Started: 7/31/2024

NCT06348576 Phase 3 RECRUITING

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Started: 5/20/2024

NCT06052748 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-223

Started: 2/15/2024

NCT06747936 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Started: 2/1/2025

NCT06448962 Phase 3 COMPLETED

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Started: 10/22/2020

NCT04825561 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-208

Started: 6/9/2021

NCT05131997 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

Started: 11/16/2021

NCT04158076 Phase 3 COMPLETED

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

Started: 1/23/2020

NCT03872232 Phase 3 COMPLETED

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

Started: 2/26/2019

NCT04066530 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-203

Started: 9/23/2019

NCT05631990 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-209

Started: 4/5/2023

NCT04218552 Phase 2 COMPLETED

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

Started: 2/25/2020

NCT07550231 Phase 2 NOT YET RECRUITING

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

Started: 6/1/2026

NCT07444385 Phase 1 RECRUITING

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

Started: 2/26/2026

NCT07385235 Phase 1 RECRUITING

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Started: 1/27/2026

NCT06932705 Phase 1 RECRUITING

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Started: 4/1/2025

NCT06884098 Phase 1 RECRUITING

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Started: 3/10/2025

NCT07521241 Phase 1 NOT YET RECRUITING

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Started: 5/1/2026

NCT07495514 Phase 1 ENROLLING BY INVITATION

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers

Started: 2/1/2026

NCT07476157 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects

Started: 4/1/2026

NCT07385248 Phase 1 NOT YET RECRUITING

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

Started: 4/1/2026

NCT07312799 Phase 1 NOT YET RECRUITING

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

Started: 1/27/2026

NCT07312773 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

Started: 1/23/2026

NCT07152873 Phase 1 NOT YET RECRUITING

A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A

Started: 12/1/2025

NCT06884085 Phase 1 COMPLETED

A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

Started: 7/12/2025

NCT07103278 Phase 1 NOT YET RECRUITING

A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers

Started: 12/1/2025

NCT06902818 Phase 1 COMPLETED

The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Started: 3/21/2025

NCT06858865 Phase 1 COMPLETED

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282

Started: 7/12/2025

NCT06976489 Phase 1 NOT YET RECRUITING

The Food Effect on PK Characteristics and Safety Profiles of PA-111

Started: 5/1/2025

NCT06916130 Phase 1 NOT YET RECRUITING

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

Started: 4/21/2025

NCT05703282 Phase 1 COMPLETED

A Study to Assess the Safety and Pharmacokinetics of AD-104-A

Started: 3/13/2023

NCT06025773 Phase 1 COMPLETED

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

Started: 9/15/2023

NCT05202405 Phase 1 COMPLETED

A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

Started: 1/5/2022

NCT05062876 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-214 and AD-2141

Started: 11/1/2021

NCT04690868 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131

Started: 10/15/2021

NCT05128591 Phase 1 COMPLETED

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

Started: 11/9/2021

NCT04755985 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132

Started: 3/21/2021

NCT04622358 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

Started: 12/5/2020

NCT04600284 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

Started: 11/16/2020

NCT04494243 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

Started: 8/28/2020

NCT03980756 Phase 1 COMPLETED

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

Started: 6/5/2019

NCT04214808 Phase 1 COMPLETED

To Evaluate the Pharmacokinetics and Safety of AD-208

Started: 1/3/2020

NCT04375865 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112

Started: 5/30/2020

NCT03824171 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers

Started: 2/28/2019

NCT03764462 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers

Started: 12/14/2018

NCT03632668 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Started: 9/28/2018

NCT03586037 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Started: 6/12/2018

NCT07538466 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Started: 4/1/2026

Drug Candidates

AD-230, AD-2301 AD-117 AD-118, AD-1181 AD-116, AD-1161 AD-229 AD-2291 AD-115A, AD-1151 Treatment A(AD-2321) Treatment B(AD-2322) Treatment C(AD-2321+AD-2322)
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 8/14/2025
Trials (12 months): 14
Completed Trials: 29
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.